EA201990835A2 - Режимы дозирования антипрогестинов - Google Patents

Режимы дозирования антипрогестинов

Info

Publication number
EA201990835A2
EA201990835A2 EA201990835A EA201990835A EA201990835A2 EA 201990835 A2 EA201990835 A2 EA 201990835A2 EA 201990835 A EA201990835 A EA 201990835A EA 201990835 A EA201990835 A EA 201990835A EA 201990835 A2 EA201990835 A2 EA 201990835A2
Authority
EA
Eurasian Patent Office
Prior art keywords
estrogen
endometriosis
treatment
present
women
Prior art date
Application number
EA201990835A
Other languages
English (en)
Other versions
EA201990835A3 (ru
Inventor
Джозеф С. Подольски
Original Assignee
Репрос Терапьютикс Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Репрос Терапьютикс Инк. filed Critical Репрос Терапьютикс Инк.
Publication of EA201990835A2 publication Critical patent/EA201990835A2/ru
Publication of EA201990835A3 publication Critical patent/EA201990835A3/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/36—Antigestagens

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)

Abstract

Настоящее изобретение относится к способам введения композиций, включающих в себя антагонист рецепторов прогестерона, для применения при лечении эстрогензависимых состояний. Изобретение также указывает на способы лечения болей, связанных с эндометриозом. Композиции могут вводиться женщинам, больным эндометриозом, а также женщинам, проходящим лечение эстрогеном и/или селективными модуляторами рецепторов эстрогена (СМРЭ). В некоторых вариантах осуществления настоящее изобретение представляет способ для подавления эндометриального разрастания.
EA201990835A 2008-04-28 2009-04-27 Режимы дозирования антипрогестинов EA201990835A3 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US4847208P 2008-04-28 2008-04-28

Publications (2)

Publication Number Publication Date
EA201990835A2 true EA201990835A2 (ru) 2019-08-30
EA201990835A3 EA201990835A3 (ru) 2019-12-30

Family

ID=40751037

Family Applications (3)

Application Number Title Priority Date Filing Date
EA201990835A EA201990835A3 (ru) 2008-04-28 2009-04-27 Режимы дозирования антипрогестинов
EA201071249A EA201071249A1 (ru) 2008-04-28 2009-04-27 Режимы дозирования антипрогестинов
EA201401347A EA032646B1 (ru) 2008-04-28 2009-04-27 Режимы дозирования антипрогестинов

Family Applications After (2)

Application Number Title Priority Date Filing Date
EA201071249A EA201071249A1 (ru) 2008-04-28 2009-04-27 Режимы дозирования антипрогестинов
EA201401347A EA032646B1 (ru) 2008-04-28 2009-04-27 Режимы дозирования антипрогестинов

Country Status (24)

Country Link
US (2) US8426394B2 (ru)
EP (1) EP2293797B1 (ru)
JP (1) JP5791499B2 (ru)
KR (2) KR20110014162A (ru)
CN (2) CN102014923A (ru)
AR (1) AR071516A1 (ru)
AU (1) AU2009241355B2 (ru)
BR (1) BRPI0911563A2 (ru)
CA (1) CA2722753C (ru)
CL (1) CL2009001010A1 (ru)
DK (1) DK2293797T3 (ru)
EA (3) EA201990835A3 (ru)
ES (1) ES2561810T3 (ru)
IL (1) IL208844A0 (ru)
ME (1) ME01123B (ru)
MX (1) MX2010011272A (ru)
MY (1) MY161059A (ru)
NI (1) NI201000183A (ru)
NZ (1) NZ589533A (ru)
SG (1) SG10201408483QA (ru)
TW (1) TWI477276B (ru)
UA (1) UA102849C2 (ru)
WO (1) WO2009134718A1 (ru)
ZA (1) ZA201007529B (ru)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI539953B (zh) * 2008-04-28 2016-07-01 瑞波若斯治療學公司 用於治療乳癌之組成物和方法
TWI477276B (zh) 2008-04-28 2015-03-21 Repros Therapeutics Inc 抗黃體素給藥方案
HUP0900487A2 (hu) * 2009-08-05 2011-03-28 Richter Gedeon Nyrt 17-acetoxi-11ß-[4-(dimetil-amino)-fenil]-21-metoxi-19-norpregna-4,9-dién-3,20-dion új kristályos polimorf módosulata és eljárás elõállítására
UA113283C2 (xx) * 2010-12-23 2017-01-10 19-норстероїди і їх застосування для лікування прогестеронзалежних станів
EP2471537A1 (en) 2010-12-30 2012-07-04 PregLem S.A. Treatment of pain associated with dislocation of basal endometrium
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
JP6285866B2 (ja) 2011-11-23 2018-02-28 セラピューティックスエムディー インコーポレーテッドＴｈｅｒａｐｅｕｔｉｃｓｍｄ， Ｉｎｃ． 天然複合ホルモン補充製剤および療法
BR112014029131B1 (pt) * 2012-05-31 2021-03-09 Allergan Pharmaceuticals International Limited cápsula de mucoadesivo
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
CN104755087A (zh) * 2012-11-02 2015-07-01 利普生物药剂公司 治疗孕酮依赖性病况的方法和组合物
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
HU230381B1 (hu) * 2014-02-17 2016-03-29 Richter Gedeon Nyrt Ipari eljárás szteroid intermedier előállítására
KR20170005819A (ko) 2014-05-22 2017-01-16 쎄러퓨틱스엠디, 인코퍼레이티드 천연 복합 호르몬 대체 제형 및 요법
RU2016141135A (ru) 2014-07-29 2018-08-28 Терапьютиксмд, Инк. Трансдермальный крем
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
WO2017173071A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2377418A1 (fr) * 1977-01-13 1978-08-11 Roussel Uclaf Nouveaux derives steroides 4,9-dieniques 11b-substitues, leur procede de preparation et leur application comme medicaments
FR2521565B1 (fr) 1982-02-17 1985-07-05 Dior Sa Parfums Christian Melange pulverulent de constituants lipidiques et de constituants hydrophobes, procede pour le preparer, phases lamellaires lipidiques hydratees et procede de fabrication, compositions pharmaceutiques ou cosmetiques comportant des phases lamellaires lipidiques hydratees
FR2522328B1 (fr) 1982-03-01 1986-02-14 Roussel Uclaf Nouveaux produits derives de la structure 3-ceto 4,9 19-nor steroides, leur procede de preparation et leur application comme medicaments
FR2534487B1 (fr) 1982-10-15 1988-06-10 Dior Christian Parfums Procede d'homogeneisation de dispersions de phases lamellaires lipidiques hydratees, et suspensions obtenues par ce procede
WO1985002092A1 (en) 1983-11-14 1985-05-23 Bio-Mimetics Inc. Bioadhesive compositions and methods of treatment therewith
FR2598421B1 (fr) 1986-05-06 1988-08-19 Roussel Uclaf Nouveaux produits 19-nor ou 19-nor d-homo steroides substitues en position 11b par un radical phenyle portant un radical alkynyle, leur procede de preparation, leur application comme medicaments et les compositions les renfermant
US5077211A (en) 1988-07-06 1991-12-31 Applied Genetics, Inc. Purification and administration of dna repair enzymes
US5439913A (en) * 1992-05-12 1995-08-08 Schering Aktiengesellschaft Contraception method using competitive progesterone antagonists and novel compounds useful therein
US5468741A (en) 1993-05-28 1995-11-21 The Regents Of The University Of California Use of low levels of mifepristone to treat leiomyomata
WO1995013802A1 (en) * 1993-11-16 1995-05-26 Schering Aktiengesellschaft Treatment of uterine contractility disorders with a nitric oxide synthase substrate and/or donor, or a nitric oxide inhibitor
DE4426601A1 (de) * 1994-07-27 1996-02-01 Schering Ag Verwendung eines Kombinationsproduktes enthaltend einen kompetitiven Progesteronantagonisten und ein Gestagen zur Herstellung eines Arzneimittels zur Behandlung der Endometriose oder des Leiomyomata uteri
EP0806952B1 (de) * 1995-02-02 2003-04-02 Schering Aktiengesellschaft Verwendung von kompetitiven progesteronantagonisten für die herstellung von arzneimitteln zur behandlung von dysfunktionellen uterinen blutungen
US6900193B1 (en) * 1996-05-01 2005-05-31 The United States Of America As Represented By The Department Of Health And Human Services Structural modification of 19-norprogesterone I: 17-α-substituted-11-β-substituted-4-aryl and 21-substituted 19-norpregnadienedione as new antiprogestational agents
HU230492B1 (hu) * 1996-05-01 2016-08-29 The Government Of The United States Of America Új progesztációt gátló szerként használható 21-helyzetben szubsztituált progeszteron-származékok, ezeket tartalmazó gyógyszerkészítmények, alkalmazásuk
AU2805397A (en) 1996-08-30 1998-03-19 Population Council, Center For Biomedical Research, The Vaginal application mifepristone
US6020328A (en) 1998-03-06 2000-02-01 Research Triangle Institute 20-keto-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties
US6172052B1 (en) 1998-12-04 2001-01-09 Research Triangle Institute 17β-acyl-17α-propynyl-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties
EP1008443A1 (de) 1998-12-08 2000-06-14 Alusuisse Technology & Management AG Sterilisierbarer Folienverbund für Verpackungszwecke
US6740645B1 (en) 1999-09-03 2004-05-25 Research Triangle Institute 17β-acyl-17α-propynyl-11β-(cyclic amino) aryl steroids and their derivatives having antagonist hormonal properties
EP1265911B1 (en) * 2000-03-17 2008-05-21 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES 17-alpha-substituted-11-beta-substituted-4-aryl and 21-substituted 19-norpregnadienedione as antiprogestational agents
IN191020B (ru) * 2000-03-28 2003-09-13 Dabur Res Foundation
KR100464159B1 (ko) 2000-04-03 2005-01-03 아스텐존슨 인코포레이티드 예비 권축형 연락부 부재
ATE310522T1 (de) * 2000-10-18 2005-12-15 Schering Ag Verwendung von antiprogestinen zur prophylaxe und behandlung von hormonabhängigen erkrankungen
CA2777199A1 (en) 2001-07-09 2003-01-23 Repros Therapeutics Inc. Methods and materials for the treatment of testosterone deficiency in men
AU2004233997C1 (en) 2003-04-29 2014-01-30 Massachusetts Institiute Of Technology Methods and devices for the sustained release of multiple drugs
EP1593376A1 (en) 2004-05-04 2005-11-09 Warner-Lambert Company LLC Improved pullulan capsules
KR101229701B1 (ko) * 2004-07-09 2013-02-05 라보라토이레 에이치알에이 파르마 프로게스테론 수용체 조절제를 함유하는 서방형 조성물
GT200500185A (es) * 2004-08-09 2006-04-10 Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos
DE102005028970A1 (de) * 2005-06-22 2006-12-28 Siemens Ag Piezoakter mit gesteigertem Hubvermögen
DE102005030294A1 (de) * 2005-06-24 2007-01-04 Schering Ag Nichtsteroidale Progesteronrezeptor-Modulatoren
WO2007103510A2 (en) * 2006-03-08 2007-09-13 Danco Laboratories Llc Methods, dosing regimens & medications using anti-progestational agents for the treatment of disorders
CA2673128C (en) * 2006-10-24 2018-07-03 Repros Therapeutics Inc. Compositions and methods for suppressing endometrial proliferation
JP2010516686A (ja) * 2007-01-17 2010-05-20 レプロス セラピューティクス インコーポレイティド ステロイド誘導体の安定性向上のための方法
JP5379121B2 (ja) 2007-04-05 2013-12-25 ユニバーシティ・オブ・カンザス プルランを含む速溶性医薬組成物
PL2148681T3 (pl) * 2007-04-20 2016-09-30 Selektywny modulator progesteronu w leczeniu krwawienia z macicy
TWI477276B (zh) 2008-04-28 2015-03-21 Repros Therapeutics Inc 抗黃體素給藥方案
WO2011039680A1 (en) 2009-09-29 2011-04-07 Koninklijke Philips Electronics N.V. Intrauterine electronic capsule for administering a substance

Also Published As

Publication number Publication date
WO2009134718A1 (en) 2009-11-05
AU2009241355A1 (en) 2009-11-05
SG10201408483QA (en) 2015-02-27
JP5791499B2 (ja) 2015-10-07
CN105616427A (zh) 2016-06-01
CN102014923A (zh) 2011-04-13
ME01123B (me) 2013-03-20
EP2293797A1 (en) 2011-03-16
CA2722753C (en) 2018-07-03
US20110046098A1 (en) 2011-02-24
EP2293797B1 (en) 2015-11-11
WO2009134718A8 (en) 2010-09-23
KR20110014162A (ko) 2011-02-10
EA201071249A1 (ru) 2011-08-30
KR20130059442A (ko) 2013-06-05
IL208844A0 (en) 2011-01-31
EA032646B1 (ru) 2019-06-28
CL2009001010A1 (es) 2009-06-19
US8426394B2 (en) 2013-04-23
AU2009241355B2 (en) 2013-11-14
JP2011518845A (ja) 2011-06-30
NZ589533A (en) 2012-06-29
US8735381B2 (en) 2014-05-27
EA201990835A3 (ru) 2019-12-30
TWI477276B (zh) 2015-03-21
MY161059A (en) 2017-04-14
CA2722753A1 (en) 2009-11-05
US20130289008A1 (en) 2013-10-31
BRPI0911563A2 (pt) 2016-07-12
ZA201007529B (en) 2011-07-27
MX2010011272A (es) 2010-12-21
AR071516A1 (es) 2010-06-23
NI201000183A (es) 2012-06-06
ES2561810T3 (es) 2016-03-01
TW200950786A (en) 2009-12-16
UA102849C2 (ru) 2013-08-27
DK2293797T3 (en) 2016-01-11
EA201401347A1 (ru) 2015-07-30

Similar Documents

Publication Publication Date Title
EA201990835A2 (ru) Режимы дозирования антипрогестинов
EA200970409A1 (ru) Композиции и способы, предназначенные для подавления эндометриальной пролиферации
EA200700118A1 (ru) Амидосоединения и их применение в качестве лекарственных средств
EA200900203A1 (ru) Избирательные модуляторы рецептора андрогенов, их аналоги, производные и применение
DE602007010781D1 (de) N- (phenylmethyl) -2- (1h-pyrazol-4-yl) acetamid-derivate als p2x7-antagonisten zur behandlung von schmerzen, entzündungen und neurodegeneration
MY161549A (en) Progesterone antagonists such as cdb-4124 in the treatment of breast cancer
EA201390803A1 (ru) Ингибиторы бромодомена и их применение
EA200870185A1 (ru) Комбинации ингибиторов ang2 и vegf
EA201071038A1 (ru) Производные 1-бензил-3-гидроксиметилиндазола и их применение для лечения заболеваний, основанных на экспрессии mcp-1, cx3cr1 и p40
EA201400002A1 (ru) Способы лечения заболеваний сетчатки
MX2010009625A (es) Derivados de 1-bencil-3-hidroximetilindazol y uso de los mismos en el tratamiento de enfermedades basadas en la expresion de mcp-1, cx3cr1 y p40.
MX2013002390A (es) Tratamiento de infarto de miocardio usando antagonistas de tgf-beta.
EA201001749A1 (ru) Способ лечения недифференцированного артрита
EA201171215A1 (ru) Стоматологическое анестезирующее средство для интраназального введения, содержащее тетракаин и вазоконстриктор
BRPI0907220A2 (pt) métodos de tratar distúrbios de perda óssea usando um antagonista de gm-csf
EA201391702A1 (ru) Интраназальные тестостероновые составы с пониженной дозировкой в виде геля и их применение для лечения аноргазмии или гипоактивного расстройства сексуального желания
WO2009134725A3 (en) Monomethylamine progesteron antagonists such as cdb-4453 in the treatment of endometriosis, uterine fibroids, dysmenorrhea, breast cancer etc
EA201071146A1 (ru) Способы диагностирования, предупреждения и лечения болезней, связанных с костной массой
EA201990106A1 (ru) Режим приема селективного модулятора рецептора прогестерона (sprm)
EA201491614A1 (ru) Способ лечения гинекологических заболеваний
EA201591793A1 (ru) Лактамные соединения в качестве селективных агонистов ep4-рецепторов для применения при лечении опосредованных ep4 заболеваний и состояний
CL2011001034A1 (es) Compuestos derivados de pirrolidina; compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como endometriosis, fibroides uterinos, menorragia, entre otras.
EA201590522A1 (ru) Способы введения рифаксимина для снижения веса и лечения ожирения
EA201071350A1 (ru) Композиции и способы для лечения воспаления роговицы
UA98124C2 (ru) Применение антагониста прогестерона для лечения эндометриоза